Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | STS | P08842 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3878960 | 0.98 | F2 (0.52) | F2LMNASTSTSHRMAPT | |
| SCHEMBL1315543 | 0.82 | LMNA (0.58) | F2LMNATSHRMAPTKMT2A | |
| SCHEMBL27342456 | 0.81 | AKR1C3 (0.53) | LMNASTSMAPTKMT2AALDH1A1 | |
| SCHEMBL4818821 | 0.80 | LMNA (0.56) | F2LMNATSHRMAPTKMT2A | |
| SCHEMBL27753578 | 0.79 | TDP1 (0.55) | LMNASTSMAPTKMT2APOLB | |
| SCHEMBL27577615 | 0.79 | HSD17B10 (0.52) | LMNASTSTSHRKMT2APOLB | |
| SCHEMBL27797225 | 0.79 | STS (0.58) | STSALDH1A1CA2CA1CA9 | |
| SCHEMBL2902948 | 0.78 | LMNA (0.54) | F2LMNATSHRMAPTKMT2A | |
| SCHEMBL28895613 | 0.78 | LMNA (0.54) | F2LMNATSHRMAPTKMT2A | |
| SCHEMBL1020413 | 0.78 | TSHR (0.56) | F2LMNATSHRMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112326642-A | Atmospheric pollution gas monitoring facilities based on spectral chromatographic analysis | 方明科 | 2021-02-05 | — | — | CN | claimed |
| CN-112255223-A | High-efficiency monitoring method for peripheral polluted gas in industrial area | 方明科 | 2021-01-22 | — | — | CN | claimed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | claimed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | claimed |
| US-20070197488-A1 | Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds | BAYER SCHERING PHARMA AG (DE) | 2007-08-23 | — | — | US | claimed |
| CN-1993375-A | Steroid prodrugs with androgenic effect | SCHERING AG (DE) | 2007-07-04 | — | — | CN | claimed |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | US | claimed |
| US-20050288267-A1 | Estradiol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | US | claimed |
| US-20050282793-A1 | Steroid prodrugs with androgenic action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-22 | — | — | US | claimed |
| US-20050277625-A1 | Estriol and estetrol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-15 | — | — | US | claimed |
| US-6600016-B1 | Solid support for use in the biosynthesis of combinatorial libraries | ADVANCED SYNTECH LLC | 2003-07-29 | — | — | US | claimed |
| CN-117599214-A | Cisplatin diagnosis and treatment probe targeting carbonic anhydrase and preparation method and application thereof | 南京大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-112326642-A | Atmospheric pollution gas monitoring facilities based on spectral chromatographic analysis | 方明科 | 2021-02-05 | — | — | CN | disclosed |
| CN-112255223-A | High-efficiency monitoring method for peripheral polluted gas in industrial area | 方明科 | 2021-01-22 | — | — | CN | disclosed |
| EP-3019172-B1 | PRO-DRUG FORMING COMPOUNDS | EVESTRA INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-6600016-B1 | Solid support for use in the biosynthesis of combinatorial libraries | ADVANCED SYNTECH LLC | 2003-07-29 | — | — | US | disclosed |
| US-6583130-B1 | Substituted with acyl, oxycarbonyl, aminocarbonyl, sulfonyl, or aminosulfonyl; inhibit steroid sulfatase, do not exhibit any estrogenic effect and will not yield any estrogenic products on hydrolysis; treatment of estrogen-dependent tumors | SCHERING AG (DE) | 2003-06-24 | — | — | US | disclosed |
| WO-2002022146-A2 | COMPONENTS OF CANOLA FOR TREATING HYPERLIPIDEMIA | KGK SYNERGIZE (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-0321090-A2 | Isoxazolidine-3,5-diones in the treatment of hyperlipidemia | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | F2 2270/4885LMNA 4383/4885STS 4105/4885 |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | CYP19A1, ESR2, HSD17B11 | F2 1228/4885LMNA 3785/4885STS 229/4885 |
| US-20050288267-A1 | Estradiol prodrugs | CYP19A1, ESR1, HSD17B11 | F2 305/4885LMNA 2824/4885STS 104/4885 |
| US-20050282793-A1 | Steroid prodrugs with androgenic action | CYP21A2, CYP17A1, NR5A1 | F2 1408/4885LMNA 2550/4885STS 97/4885 |
| US-20070197488-A1 | Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds | ESR2, ESR1, CYP19A1 | F2 1247/4885LMNA 3952/4885STS 245/4885 |
| US-20050277625-A1 | Estriol and estetrol prodrugs | HSD17B11, CYP19A1, ESR1 | F2 324/4885LMNA 2967/4885STS 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.